Celladon
Corp. (Nasdaq: CLDN) reported disappointing results from a Phase 2b CUPID2
trial for its cardiovascular gene therapy agent MYDICAR(R) prompting a
downgrade. Shares of the biotechnology firm plummeted $10.99 to $2.69.
Celladon reports disappointing trial results
April 27, 2015 at 14:34 PM EDT